Major histocompatibility (MHC) class II antigen presenting molecules play a seminal role on professional antigen presenting cells in the T-cell activation process and therefore in regulating the immune response. The role of MHC class II expression on tumor cells, particularly tumor cells of mesenchymal or parenchymal origin has been more controversial. Nevertheless, there is a large body of literature indicating that tumor cell MHC class II can affect tumor development. Tumor cell MHC class II expression has been shown to mediate tumor antigen dependent anti-tumor T-cell activity 1, 2) ; to mediate apoptosis 3)
Major histocompatibility (MHC) class II antigen presenting molecules play a seminal role on professional antigen presenting cells in the T-cell activation process and therefore in regulating the immune response. The role of MHC class II expression on tumor cells, particularly tumor cells of mesenchymal or parenchymal origin has been more controversial. Nevertheless, there is a large body of literature indicating that tumor cell MHC class II can affect tumor development. Tumor cell MHC class II expression has been shown to mediate tumor antigen dependent anti-tumor T-cell activity 1, 2) ; to mediate apoptosis 3) ; and to mediate tolerance. 4) Furthermore, there are numerous tumor associated mechanisms, in some cases mechanisms that are indisputably associated with tumor development, involved in tumor cell regulation of MHC class II. For example, mitogen activated protein kinase (MAPK) activity in melanoma is associated with high levels of expression of human leukocyte antigen (HLA)-DR, the most important MHC class II molecule in humans.
5)
Also, HLA-DR induction by interferon-gamma (IFN-g) is abolished or highly limited, depending on the cell type, in retinoblastoma protein (Rb)-defective tumor cells, including Rb-defective non-small cell lung cancer cells. [6] [7] [8] The histon deacetylase (HDAC) inhibitors, sodium butyrate and trichostatin A can induce MHC class II surface expression in tumor cells. 8, 9) The requirement of IFN-g appears to be variable, but at a minimum, the combination of IFN-g treatment and the above HDAC inhibitors has always led to the rescue of MHC class II surface expression. 10) However, this process has never been reported for a class I specific HDAC inhibitor and in particular has never been reported for an HDAC inhibitor in clinical trials. This is an important issue, because knowledge of the potential effect of an HDAC inhibitor, used for patient therapy, on MHC class II expression could affect the interpretations of clinical outcomes. The MS-275 class I HDAC inhibitor is currently being used in clinical trials for non-small cell lung cancer (http://clinicaltrials.gov/). Thus, we determined whether MS-275 could contribute to the induction of surface HLA-DR on non-small cell lung carcinoma cells.
MATERIALS AND METHODS
For Fig. 2 , H2009 non-small cell lung carcinoma cells were treated with 400 units IFN-g per ml for 48 h and analyzed by flow cytometry exactly as described. 7) H2009 cells were cultured in RPMI, 10% fetal bovine serum, with pyruvate, penicillin, streptomycin and glutamate supplements. H2009 cells were treated with 1.6 mg/ml of MS-275 (Sigma-Aldrich) 24 h after the IFN-g treatment, i.e., for the last 24 h of the IFN-g treatment. For Fig. 3A , H2009 cells were transfected with the indicated plasmids and treated with IFN-g exactly as described.
8) Cells were treated with 1.6 mg/ml of MS-275, as indicated, 4 h following the completion of the DNA transfection protocol. Luciferase assays were performed 24 h after completion of the DNA transfection protocol. Chromatin immunoprecipitation (ChIP) assays were conducted as described.
11) The anti-HDAC1 and control antibodies were purchased from Abcam. Primers spanning the Yin Yang-1 (YY1) site of HLA-DRA were used in real time polymerase chain reaction (PCR) to quantify the ChIP results. Primer sequences are as follows: sense 5Ј-GAA GTC AGA TTG GGG TTA A-3Ј; antisense 5Ј-CAG CTA TGA TGA AAA ATC CT-3Ј. iQ SYBR Green Supermix was purchased from BioRad, and primers were used at a final concentration of 400 nM. The reactions were initially denatured at 95°C for 5 min, followed by a 30 s denaturation at 95°C a 30 s annealing at 53°C, and a 30 s extension at 72°C. These steps were repeated 60 times, and samples were read by the iCycler after each extension. A melt curve was performed at the end of the PCR to verify products. IFN-g is inhibited by HDAC activity, most likely tethered to the gene for the large HLA-DR subunit, the HLA-DRA gene, by YY1 (Fig. 1) . To determine whether MS-275 could rescue the induction of HLA-DR, we treated the Rb-defective, H2009 non-small cell lung carcinoma cells with IFN-g and MS-275 and assayed for HLA-DR surface expression by flow cytometry (Fig. 2) . Results indicated that MS-275 facilitated substantial induction of cell surface HLA-DR, when compared to normal skin fibroblasts, a positive control for the normal level of the HLA-DR IFN-g response. This result is consistent with results obtained with other HDAC inhibitors 8) and indicates that an HDAC inhibitor suitable for patient therapy can facilitate surface HLA-DR induction.
To further clarify the initial results, we determined whether the YY1 site, which tethers a YY1-HDAC complex to the HLA-DRA promoter, 8) was related to the MS-275 effect. We transfected an HLA-DRA promoter luciferase construct, termed pDRA, and pDRA lacking the YY1 site, termed pDRA YY1mut, into the H2009 cells. The cells were treated with IFN-g and were treated with MS-275, or left untreated. Results indicated that lack of the YY1 site reduces the MS-275 effect (Fig. 3A) , further supporting the conclusion that the MS-275 facilitated induction of surface HLA-DR is due to the inhibition of an HDAC tethered to the HLA-DRA gene by YY1. As in previous experiments with other HDAC inhibitors, 8) eliminating the binding of YY1 does not eliminate the entire HDAC inhibitor effect, indicating that HDACs are tethered to the pDRA construct at other sites in addition to the YY1 binding site.
We next performed a ChIP assay for an HDAC bound to the endogenous HLA-DRA gene in the H2009 cells. The cells were fixed, the chromatin was sheared, and the sheared chromatin was immuno-precipitated by anti-HDAC1 or a control antibody. Results indicated that HDAC1, or an HDAC cross-reactive with the anti-HDAC1, was bound to the HLA-DRA gene (Figs. 3B, C) . While a great deal of data has led to the basic picture of the status of the HLA-DRA promoter in Rb-defective and Rb-positive cells (Fig. 1) , these results are the first data directly supporting the conclusion that Rb-defective cells have an HDAC tethered to the endogenous HLA-DRA gene at or near the YY1 site. In Rb defective cells, the endogenous HLA-DRA promoter is inhibited by Oct-1, and this is consistent with transient transfection experiments with the wild-type HLA-DRA and Oct-1 binding site-mutated, promoter reporter constructs. The endogenous HLA-DRA promoter is known to be inhibited by HDAC activity and is known to be occupied by YY1 in Rb-defective cells. Following Rb-tranformation, it is known that (i) the endogenous Oct-1 becomes largely phosphorylated and thereby loses its DNA binding activity; (ii) that the indicated, positive acting promoter binding proteins occupy the endogenous HLA-DRA promoter; and (iii) that the endogenous promoter, as well as the promoters for HLA-DRB, -DPA, and DPB become responsive to IFN-g. The fate of YY1, particularly for the endogenous HLA-DRA promoter, after Rb-transformation, is unknown, but YY1 presumably no longer functions as a negative factor. Abbreviatrions: IFN, interferon; HDAC, histone deacetylase; X, Y, O and YY1 represent the HLA-DRA promoter binding sites for regulatory factor X (RFX), nuclear factor-Y (NF-Y), the Oct-1 protein; and Yin Yang-1 (YY1), respectively. CIITA, class II transactivator. 
